1. Home
  2. DSP vs SKYE Comparison

DSP vs SKYE Comparison

Compare DSP & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Viant Technology Inc.

DSP

Viant Technology Inc.

HOLD

Current Price

$12.66

Market Cap

279.6M

Sector

Technology

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$1.78

Market Cap

9.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DSP
SKYE
Founded
1999
2012
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
279.6M
9.0M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
DSP
SKYE
Price
$12.66
$1.78
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
3
Target Price
$17.81
$15.00
AVG Volume (30 Days)
375.3K
81.7K
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
157.14
N/A
EPS
N/A
N/A
Revenue
$344,201,000.00
N/A
Revenue This Year
$20.27
N/A
Revenue Next Year
$16.88
N/A
P/E Ratio
N/A
N/A
Revenue Growth
19.00
N/A
52 Week Low
$8.11
$0.26
52 Week High
$14.80
$4.99

Technical Indicators

Market Signals
Indicator
DSP
SKYE
Relative Strength Index (RSI) 48.82 54.89
Support Level $9.78 $1.64
Resistance Level $12.46 $2.28
Average True Range (ATR) 0.70 0.22
MACD -0.16 -0.07
Stochastic Oscillator 66.59 32.00

Price Performance

Historical Comparison
DSP
SKYE

About DSP Viant Technology Inc.

Viant Technology Inc is an advertising technology company engaged in providing a cloud-based demand-side platform (DSP) for programmatic advertising. The company enables marketers and advertising agencies to plan, buy, and measure digital advertising campaigns across multiple channels, including connected TV, streaming audio, mobile, desktop, and digital out-of-home. Its platform leverages data integrations and proprietary identity solutions to deliver targeted advertising, audience insights, and performance measurement.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: